A review of 331 rhabdomyosarcoma cases in patients treated between 1991 and 2002 in Japan

International Journal of Clinical Oncology

Volumn 12, Issue 2, 2007, Pages 137-145

  Hosoi, Hajime ^a   Teramukai, Satoshi ^b   Matsumoto, Yoshifumi ^a   Tsuchiya, Kunihiko ^a   Iehara, Tomoko ^a   Hara, Jun Ichi ^c   Mitsui, Tetsuo ^d   Kaneko, Michio ^e   Hatae, Yoshiro ^f   Hayashi, Yutaka ^g   Mabuchi, Osamu ^h   Adachi, Naoto ⁱ   Morikawa, Yasuhide ^j   Nishimura, Shin Ichiro ^k   Kumagai, Masaaki ^l   Takamatsu, Hideo ^m   Sawada, Tadashi ^a   Sugimoto, Tohru ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^e UNIVERSITY OF TSUKUBA   (Japan)

^f HOKKAIDO CANCER CENTER   (Japan)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h KOBE CHILDREN S HOSPITAL   (Japan)

ⁱ KUMAMOTO UNIVERSITY   (Japan)

^j KEIO UNIVERSITY   (Japan)

^k HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^l NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^m KAGOSHIMA UNIVERSITY   (Japan)

more..

Author keywords

Japan; Rhabdomyosarcoma; Risk groups; Survival

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; PIRARUBICIN; THIOTEPA; VINCRISTINE;

ADOLESCENT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILD; CHIMERA; GENETIC ANALYSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; JAPAN; MAJOR CLINICAL STUDY; MARKER GENE; OUTCOME ASSESSMENT; PATIENT CODING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RHABDOMYOSARCOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INFANT; JAPAN; MALE; NEOPLASM STAGING; ORBITAL NEOPLASMS; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RHABDOMYOSARCOMA; RISK FACTORS; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TIME FACTORS; UROGENITAL NEOPLASMS;

EID: 34247362419     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0638-6     Document Type: Review

References (12)

1. WM Crist EA Gehan AH Ragab 1997 The Third Intergroup Rhabdomyosarcoma Study J Clin Oncol 13 610 630
2. WM Crist JR Anderson JL Meza 2001 Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease J Clin Oncol 19 3091 3102
3. Committee on Tumor Registration, Japanese Society of Pediatric Surgeons 1999 The clinical features and prognosis of rhabdomyosarcoma: follow-up studies on pediatric tumors from the Japanese Pediatric Tumor Registry 1981-1990 J Jpn Soc Pediatr Surg 35 716 738
4. Sugimoto T (2002) Rhabdomyosarcoma. A report for Grant-in-Aid (13-19) in Cancer Research, Ministry of Health, Labour and Welfare of Japan:467-468
5. T Sawada T Shikata T Matsumura 1994 Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group Prog Clin Biol Res 385 371 375
6. W Lawrence Jr JR Anderson EA Gehan HM Maurer 1997 Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group Cancer 80 1165 1170
7. W Laurence Jr EA Gehan DM Hays 1987 Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II) J Clin Oncol 5 46 54
8. PH Sorensen JC Lynch SJ Qualman 2002 PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group J Clin Oncol 20 2672 2679
9. RB Raney JR Anderson FG Barr 2001 Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V J Pediatr Hematol Oncol 23 215 220
10. J Breneman J Anderson S Donaldson 2001 Prognostic factors and outcome in children with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV Int J Radiat Oncol Biol Phys 51 A 210 118
11. H Matsubara A Makimoto T Higa 2003 Possible benefits of high-dose chemotherapy as intensive consolidation in patients with high-risk rhabdomyosarcoma who achieve complete remission with conventional chemotherapy Pediatr Hematol Oncol 20 201 210
12. J Hara Y Osugi H Ohta 1998 Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors Bone Marrow Transplant 22 7 12